Wijbrandts, C A <br/><br/>
Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.  [electronic resource] 

 -  Annals of the rheumatic diseases  Aug 2009 
 - 1316-21 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/ard.2007.086728  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antirheumatic Agents--therapeutic use<br/>Apolipoprotein A-I--blood<br/>Arthritis, Rheumatoid--blood<br/>Biomarkers--metabolism<br/>C-Reactive Protein--metabolism<br/>Cholesterol, HDL--blood<br/>Down-Regulation--drug effects<br/>Female<br/>Humans<br/>Inflammation Mediators--blood<br/>Lipids--blood<br/>Macrophage Migration-Inhibitory Factors--blood<br/>Male<br/>Middle Aged<br/>Severity of Illness Index<br/>Sex Factors<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors